Innovating Works

BIOITHAS

Activa
ScleroTest: A rapid and cost effective point of care diagnostic kit able to predict treatment response for appro... BIOITHAS tramitó un H2020: H2020-EIC-SMEInst-2018-2020 Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million...
2019-05-20 - 2019-11-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.